Dr. Rakesh K. Srivastava
Dr. Rakesh K. Srivastava is an accomplished entrepreneur and is the CEO and President of GLAX Health LLC.
WILMINGTON, DELAWARE, UNITED STATES, August 30, 2022
— Dr. Rakesh K. Srivastava’s Scientific Research
The human body is fascinating, and it is not hard to see why scientists would take a keen interest in understanding how it works. Ideally, cell division causes existing cells to multiply and form new cells. However, some of our cells might start to grow abnormally fast and spread to the rest of our tissues in a condition we now know as cancer. Dr. Rakesh Srivastava has been conducting extensive research on how to treat human diseases, cancer being one of them. Stick around to learn more about his research and GLAX LLC’s big announcement.
What is SABT2?
SABT2 is a transcription factor, and the acronym stands for unique AT-rich binding protein-2. It regulates the chromatin architecture in the cell, therefore influencing gene expression. The presence of SABT2 is also associated with the formation of cortical neurons and crucial processes such as osteoblast differentiation and craniofacial patterning.
Expression of SABT2 in human tissues
Cells in the human body vary in the way they express SABT2. However, you can expect to find it highly expressed in progenitor and stem cells. Dr. Rakesh discovered that SABT2 plays a crucial role in cancer initiation, metastasis, and progression. He also noticed that most tumors showed high levels of the SABT2 gene. Therefore, Dr. Srivastava concluded that he could use the gene as a biomarker for diagnosing cancer and develop a targeted inhibitor to prevent and treat cancer.
SABT2 inhibitors
SABT2 is known to participate in DNA replication and regulate gene expression responsible for the self-renewal of stem cells, cell division, cell cycle, pluripotency, and cell proliferation. On the flip side, SABT2 also promotes the formation of tumors by enhancing Nanog, c-Myc, Oct4, and Sox2. Cancer stem cells are responsible for resistance to drugs and cancer initiation. Since SABT2 regulates stemness, scientists have formed a link between this gene and immune suppression. Intratumoral heterogeneity and tumor antigenicity. With this crucial information, Dr. Rakesh and his able team were confident that developing a SATB2 inhibitor would eliminate cancer stem cells. SABT2 inhibitors would also make chemotherapy more advantageous to the patient and increase radio sensitivity.
GLAX LLC’s big announcement
GLAXX LLC is a biotechnology company that deals with drug development, medical research, production, and sales. Dr. Rakesh K. Srivastava is the President and CEO of this prestigious company and has been working with his able and competent team to develop targeted therapies for neurodegenerative disorders and cancer. We are pleased to mention that the Trademark Office finally issued GLAX Health a US Patent on the SABT2 inhibitor.
We all know that intellectual property is just as important as tangible assets. Therefore, the patent will prevent anyone from taking credit for Dr. Srivastava’s work and add to the ever-growing intellectual property portfolio at GLAX Health.
Dr. Rakesh K. Srivastava has specialized in drug development, nutrition, cancer, therapeutics, immunology, and diabetes for the past 30 years. His extensive knowledge has enabled him to post numerous publications, which other scientists and scholars have cited over 27,000 times. In addition to his academic prowess, Dr. Srivastava is also well-versed in investment, management, human resources, finance, and strategy.
Contact: Dr. Rakesh Srivastava
www.rksrivastava.com
Email: contact@glaxhealth.com
Rakesh Srivastava
GLAX, LLC.
Comments